CN115768427B - 癌症疗法中用于靶向降解不可靶向的kras的新型小分子 - Google Patents
癌症疗法中用于靶向降解不可靶向的kras的新型小分子 Download PDFInfo
- Publication number
- CN115768427B CN115768427B CN202180049321.9A CN202180049321A CN115768427B CN 115768427 B CN115768427 B CN 115768427B CN 202180049321 A CN202180049321 A CN 202180049321A CN 115768427 B CN115768427 B CN 115768427B
- Authority
- CN
- China
- Prior art keywords
- compound
- kras
- cancer
- compounds
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510275737.2A CN120208921A (zh) | 2020-06-04 | 2021-05-26 | 癌症疗法中用于靶向降解不可靶向的kras的新型小分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041023434 | 2020-06-04 | ||
| IN202041023434 | 2020-06-04 | ||
| PCT/IB2021/054591 WO2021245499A1 (en) | 2020-06-04 | 2021-05-26 | Novel small molecules for targeted degradation of untargetable kras in cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510275737.2A Division CN120208921A (zh) | 2020-06-04 | 2021-05-26 | 癌症疗法中用于靶向降解不可靶向的kras的新型小分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115768427A CN115768427A (zh) | 2023-03-07 |
| CN115768427B true CN115768427B (zh) | 2025-03-28 |
Family
ID=78830675
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180049321.9A Active CN115768427B (zh) | 2020-06-04 | 2021-05-26 | 癌症疗法中用于靶向降解不可靶向的kras的新型小分子 |
| CN202510275737.2A Pending CN120208921A (zh) | 2020-06-04 | 2021-05-26 | 癌症疗法中用于靶向降解不可靶向的kras的新型小分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510275737.2A Pending CN120208921A (zh) | 2020-06-04 | 2021-05-26 | 癌症疗法中用于靶向降解不可靶向的kras的新型小分子 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230202981A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4161511B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7789016B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230019937A (cg-RX-API-DMAC7.html) |
| CN (2) | CN115768427B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021284517A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022024300A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3180686A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL298672A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022015253A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI916370B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021245499A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| AU2019338207B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| US12377101B2 (en) | 2018-12-05 | 2025-08-05 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| US12655160B2 (en) | 2020-08-04 | 2026-06-16 | Mirati Therapeutics, Inc. | KRAS G12D inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| EP4216951B1 (en) | 2020-09-22 | 2026-04-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| WO2025083564A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small molecule degrader as a potential anticancer |
| WO2025083561A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel lead small molecule inhibitors on undruggable target towards anticancer activity |
| WO2025083570A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small-molecule agents in overcoming tumor regression in cancers |
| WO2025083563A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Effective therapeutic small-molecule inhibitors for metastatic cancer |
| WO2025083568A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small-molecule protein kinase inhibitors for implications in cancer treatment |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ3347A1 (fr) * | 2000-05-22 | 2001-11-29 | Aventis Pharma Inc | Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase |
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
| IL161662A0 (en) * | 2001-11-01 | 2004-09-27 | Janssen Pharmaceutica Nv | Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors) |
| WO2007075896A2 (en) * | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
| CA2795952A1 (en) * | 2010-04-16 | 2011-10-20 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| US20190284149A1 (en) * | 2014-09-12 | 2019-09-19 | Ariagen, Inc. | Aryl hydrocarbon receptor modulator |
| CN106317055A (zh) * | 2015-07-02 | 2017-01-11 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
| EP3573971A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| CN110885332B (zh) * | 2019-12-06 | 2022-03-18 | 中国人民解放军第二军医大学 | 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用 |
-
2021
- 2021-05-26 WO PCT/IB2021/054591 patent/WO2021245499A1/en not_active Ceased
- 2021-05-26 KR KR1020237000112A patent/KR20230019937A/ko active Pending
- 2021-05-26 IL IL298672A patent/IL298672A/en unknown
- 2021-05-26 CN CN202180049321.9A patent/CN115768427B/zh active Active
- 2021-05-26 MX MX2022015253A patent/MX2022015253A/es unknown
- 2021-05-26 US US18/008,332 patent/US20230202981A1/en not_active Abandoned
- 2021-05-26 AU AU2021284517A patent/AU2021284517A1/en active Pending
- 2021-05-26 BR BR112022024300A patent/BR112022024300A2/pt unknown
- 2021-05-26 CN CN202510275737.2A patent/CN120208921A/zh active Pending
- 2021-05-26 EP EP21817859.8A patent/EP4161511B1/en active Active
- 2021-05-26 JP JP2022574452A patent/JP7789016B2/ja active Active
- 2021-05-26 CA CA3180686A patent/CA3180686A1/en active Pending
- 2021-06-04 TW TW110120388A patent/TWI916370B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230019937A (ko) | 2023-02-09 |
| EP4161511B1 (en) | 2026-04-29 |
| TWI916370B (zh) | 2026-03-01 |
| MX2022015253A (es) | 2023-03-14 |
| IL298672A (en) | 2023-01-01 |
| BR112022024300A2 (pt) | 2023-01-24 |
| CA3180686A1 (en) | 2021-12-09 |
| CN115768427A (zh) | 2023-03-07 |
| US20230202981A1 (en) | 2023-06-29 |
| WO2021245499A1 (en) | 2021-12-09 |
| JP7789016B2 (ja) | 2025-12-19 |
| EP4161511A1 (en) | 2023-04-12 |
| JP2023529354A (ja) | 2023-07-10 |
| CN120208921A (zh) | 2025-06-27 |
| TW202210465A (zh) | 2022-03-16 |
| EP4161511A4 (en) | 2024-07-17 |
| AU2021284517A1 (en) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN120208921A (zh) | 癌症疗法中用于靶向降解不可靶向的kras的新型小分子 | |
| He et al. | Targeting cullin neddylation for cancer and fibrotic diseases | |
| KR102427777B1 (ko) | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 | |
| JP6193268B2 (ja) | Cdk8/cdk19選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用 | |
| AU2013235425B2 (en) | Inhibition of MCL-1 and/or BFL-1/A1 | |
| EP3773592B1 (en) | Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer | |
| CN101910182A (zh) | 抗癌剂 | |
| CN107666906A (zh) | 用于治疗癌症的方法 | |
| US20190231735A1 (en) | Methods for treating cancer | |
| Hamaguchi et al. | 305 POSTER DNA cross-linking and in vivo antitumour activity of the extended pyrrolo [2, 1-c][1, 4] benzodiazepine dimer SG2057 (DRG-16) | |
| RU2839932C1 (ru) | Новые малые молекулы для целенаправленного расщепления не поддающегося целенаправленному воздействию kras в терапии рака | |
| Zhu et al. | Regulation of the cilia as a potential treatment for senescence and tumors: A review | |
| AU2016296997B2 (en) | Chlorobenzene substituted azaaryl compounds | |
| US20210353631A1 (en) | 1,4-Benzoxazines for the Treatment of Cancers and Other Neurodegenerative Diseases | |
| Xu et al. | Current Scenario of Hydroxamic Acid Derivatives With In Vivo Antitumor Therapeutic Potential | |
| CN111718328A (zh) | 4-甲基-1h-二芳基吡唑类衍生物在制备抗肿瘤药物中的用途 | |
| US10512631B2 (en) | Chalcone compounds | |
| WO2015153866A1 (en) | Cancer therapy with ganetespib and an egfr inhibitor | |
| TW201605449A (zh) | 馬賽替尼治療結腸直腸癌的用途 | |
| Narayanan | Anticancer Effect of Indanone-Based Thiazolyl Hydrazone Derivative on P53 Mutant Colon Cancer Cell Lines: In Vitro and in Vivo Study | |
| Elrehany et al. | Chalcone-xanthine Hybrid: Its Expected Role in Treatment of Non-small Cell Lung Cancer | |
| WO2025083563A1 (en) | Effective therapeutic small-molecule inhibitors for metastatic cancer | |
| Mattiuzzo | Pharmacological studies of novel antitumoral compounds | |
| Xiao | Discovery of Novel Tubulin Polymerization Inhibitors and Survivin Inhibitors as Potential Anticancer Agents | |
| Sutton et al. | 342 POSTER 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography is an early biomarker for tumor growth inhibition of human Colo205 xenografts by the novel and selective CENP-E inhibitor, GSK923295A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |